45
Participants
Start Date
March 7, 2025
Primary Completion Date
October 11, 2027
Study Completion Date
November 7, 2028
ALXN2030
ALXN2030 will be administered subcutaneously (SC).
Placebo
Placebo will be administered SC.
Research Site, Kaohsiung City
Research Site, Seoul
Research Site, Barcelona
Research Site, New York
Research Site, New York
Research Site, Stony Brook
Research Site, Campinas
Research Site, Philadelphia
Research Site, Richmond
Research Site, Durham
Research Site, Atlanta
Research Site, Tampa
Research Site, Birmingham
Research Site, Taichung
Research Site, Cincinnati
Research Site, Ann Arbor
Research Site, Detroit
Research Site, Zaragoza
Research Site, Milwaukee
Research Site, Kansas City
Research Site, Dallas
Research Site, Houston
Research Site, Scottsdale
Research Site, Los Angeles
Research Site, Orange
Research Site, Seattle
Research Site, Shanghai
Research Site, Wuhan
Research Site, Changsha
Research Site, Guangzhou
Research Site, Nanning
Research Site, Xi'an
Research Site, Kaohsiung City
Research Site, Livingston
Research Site, Botucatu
Research Site, Porto Alegre
Research Site, São Paulo
Research Site, São Paulo
Research Site, Calgary
Research Site, Edmonton
Research Site, Vancouver
Research Site, London
Research Site, Toronto
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Birmingham
Research Site, London
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY